Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soluble fiber health claim

This article was originally published in The Tan Sheet

Executive Summary

FDA announces Feb. 6 it proposes to amend the regulation on health claims of soluble fiber reducing the risk of coronary heart disease. The agency proposes to exempt certain foods from the nutrient content requirement of low fat. FDA says, "The exemption would apply if the food exceeds this requirement due to fat content derived from whole oat sources" such as oat bran, rolled oats, whole oat flour and oatrim. The amendment would allow the use of this health claim on some whole oats products that are currently ineligible. The comment deadline is April 23. FDA is amending the health claim in response to a 1995 petition from Pepsico's Quaker Oats Co...

You may also be interested in...



Soluble fiber QHC expanded

More foods rich in soluble fiber can tout their role in reducing the risk of coronary heart disease, according to a May 1 Federal Register notice. FDA expanded the use of the qualified health claim to "any whole oat product that was previously ineligible for the claim" because fat from the whole oat source pushed the food's total fat content past the "low fat" requirement for the claim, the notice says. FDA expanded the claim in response to a petition from PepsiCo's Quaker Oats Co. (1"The Tan Sheet" Feb. 12, 2007, In Brief). The expansion will not cover foods, such as oatmeal cookies, that include other fat sources...

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel